Aspiriant LLC Sells 613 Shares of Novo Nordisk A/S (NYSE:NVO)

Aspiriant LLC cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 10.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,382 shares of the company’s stock after selling 613 shares during the period. Aspiriant LLC’s holdings in Novo Nordisk A/S were worth $641,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Aaron Wealth Advisors LLC lifted its stake in Novo Nordisk A/S by 25.7% in the 3rd quarter. Aaron Wealth Advisors LLC now owns 20,176 shares of the company’s stock worth $2,402,000 after purchasing an additional 4,119 shares in the last quarter. Stonegate Investment Group LLC raised its holdings in shares of Novo Nordisk A/S by 2.3% in the 3rd quarter. Stonegate Investment Group LLC now owns 30,291 shares of the company’s stock valued at $3,607,000 after acquiring an additional 677 shares in the last quarter. M3 Advisory Group LLC boosted its position in shares of Novo Nordisk A/S by 4.9% during the 3rd quarter. M3 Advisory Group LLC now owns 2,984 shares of the company’s stock valued at $355,000 after acquiring an additional 140 shares during the last quarter. Heirloom Wealth Management grew its holdings in shares of Novo Nordisk A/S by 1.8% during the third quarter. Heirloom Wealth Management now owns 74,610 shares of the company’s stock worth $8,884,000 after purchasing an additional 1,325 shares in the last quarter. Finally, Armstrong Fleming & Moore Inc increased its position in shares of Novo Nordisk A/S by 7.1% in the third quarter. Armstrong Fleming & Moore Inc now owns 7,532 shares of the company’s stock worth $897,000 after purchasing an additional 500 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, October 10th. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $118.13 on Friday. The company has a market capitalization of $530.11 billion, a P/E ratio of 40.46, a PEG ratio of 1.56 and a beta of 0.42. Novo Nordisk A/S has a fifty-two week low of $92.94 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a 50 day moving average price of $128.48 and a two-hundred day moving average price of $131.65.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The firm had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Analysts expect that Novo Nordisk A/S will post 3.01 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were issued a $0.5126 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 24.66%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.